发布时间：2025-09-12 09:28 Nadofaragene firadenovec is the first and only non-replicating gene therapy administered intravesically, and it is already approved and launched in the US
This represents the first filing of a novel non-chemotherapy approach in non-muscle invasive bladder cancer (NMIBC) treatment
In the Japanese Phase 3 clinical trial, 75% complete response rate was achieved with single quarterly dosing, without requiring re-induction protocols1
This acceptance highlights Ferrings ongoing commitment to establish the new standard of care for BCG-unresponsive NMIBC



SAINT PREX, Switzerland--(BUSINESS WIRE)--Ferring Pharmaceuticals Co., Ltd. announced that the PMDA has accepted the NDA for nadofaragene firadenovec for review, following submission on August 27th, 2025. This non-replicating gene therapy, administered intravesically, offers patients with NMIBC a bladder-sparing treatment option. Nadofaragene firadenovec's quarterly dosing eliminates the burd
=*=*=*=*=*=
当前为第1/10页
下一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页